[
    [
        {
            "time": "",
            "original_text": "【券商聚焦】高盛削上海医药(02607)目标价至4.2%，下调未来三年盈测 机构下调估值",
            "features": {
                "keywords": [
                    "高盛",
                    "上海医药",
                    "目标价",
                    "下调",
                    "盈测",
                    "估值"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【券商聚焦】高盛削上海医药(02607)目标价至4.2%，下调未来三年盈测 机构下调估值",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "6家药企前三季度研发投入超过10亿元，创新势头强劲",
            "features": {
                "keywords": [
                    "药企",
                    "研发投入",
                    "创新",
                    "强劲"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "6家药企前三季度研发投入超过10亿元，创新势头强劲",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "上海医药Q3财报；AZ又一高管离职；微创医疗再次收购；艾力斯伏美替尼III期达主要终点 董监高成员变化",
            "features": {
                "keywords": [
                    "上海医药",
                    "Q3财报",
                    "AZ",
                    "高管离职",
                    "微创医疗",
                    "收购",
                    "艾力斯",
                    "伏美替尼",
                    "III期",
                    "董监高变化"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "mixed",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "scores": {
                "News_content": "上海医药Q3财报；AZ又一高管离职；微创医疗再次收购；艾力斯伏美替尼III期达主要终点 董监高成员变化",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]